UBS Group Raises BioNTech (NASDAQ:BNTX) Price Target to $131.00

BioNTech (NASDAQ:BNTX) had its price objective increased by UBS Group from $97.00 to $131.00 in a research note published on Wednesday morning, Benzinga reports. UBS Group currently has a neutral rating on the stock.

Several other research analysts have also recently issued reports on BNTX. JPMorgan Chase & Co. upgraded shares of BioNTech from an underweight rating to a neutral rating and upped their target price for the company from $91.00 to $125.00 in a report on Monday, September 16th. Hsbc Global Res upgraded shares of BioNTech from a hold rating to a strong-buy rating in a research report on Friday, August 2nd. HC Wainwright reissued a buy rating and set a $113.00 price objective on shares of BioNTech in a research report on Monday, September 16th. HSBC raised BioNTech from a hold rating to a buy rating in a report on Friday, August 2nd. Finally, Deutsche Bank Aktiengesellschaft upgraded BioNTech from a hold rating to a buy rating and set a $95.00 target price on the stock in a research note on Wednesday, August 7th. Six research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of Moderate Buy and a consensus price target of $124.54.

BioNTech Stock Performance

Shares of BNTX opened at $112.28 on Wednesday. The stock has a 50-day simple moving average of $90.26 and a 200-day simple moving average of $90.47. The company has a debt-to-equity ratio of 0.01, a quick ratio of 7.40 and a current ratio of 7.54. BioNTech has a 1 year low of $76.53 and a 1 year high of $131.49. The stock has a market capitalization of $26.69 billion, a PE ratio of 227.96 and a beta of 0.23.

BioNTech (NASDAQ:BNTX) last announced its quarterly earnings data on Monday, August 5th. The company reported ($3.36) earnings per share for the quarter, missing analysts’ consensus estimates of ($2.02) by ($1.34). BioNTech had a negative net margin of 18.69% and a negative return on equity of 2.54%. The firm had revenue of $128.70 million during the quarter, compared to analyst estimates of $134.98 million. During the same quarter in the previous year, the business posted ($0.86) earnings per share. BioNTech’s revenue for the quarter was down 23.3% compared to the same quarter last year. On average, analysts predict that BioNTech will post -2.8 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in the company. GAMMA Investing LLC lifted its holdings in shares of BioNTech by 121.0% in the first quarter. GAMMA Investing LLC now owns 274 shares of the company’s stock valued at $25,000 after purchasing an additional 150 shares in the last quarter. Frazier Financial Advisors LLC purchased a new stake in BioNTech in the 4th quarter valued at approximately $30,000. Covestor Ltd grew its holdings in BioNTech by 47.2% during the 1st quarter. Covestor Ltd now owns 415 shares of the company’s stock valued at $38,000 after buying an additional 133 shares during the last quarter. EverSource Wealth Advisors LLC increased its position in BioNTech by 106.3% during the first quarter. EverSource Wealth Advisors LLC now owns 489 shares of the company’s stock worth $43,000 after buying an additional 252 shares in the last quarter. Finally, Crewe Advisors LLC acquired a new position in shares of BioNTech in the first quarter worth $75,000. Institutional investors and hedge funds own 15.52% of the company’s stock.

About BioNTech

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.